Lv5
1540 积分 2025-01-05 加入
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
14小时前
待确认
Quantitative signal detection using spontaneous ADR reporting
14小时前
待确认
Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)
14小时前
待确认
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
14小时前
待确认
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
14小时前
待确认
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
15小时前
待确认
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
15小时前
待确认
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
15小时前
待确认
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
15小时前
待确认
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma
15小时前
待确认
皖公网安备34019202002308
